Pharmaceutical Industry GlobalPharma
Turnkey regulatory solutions for life sciences, from specialized manufacturing licenses to WHO-GMP and international registration support.
Regulatory Landscape
India is the world's pharmacy, supplying high-quality generic medicines to over 200 countries. The regulatory environment is governed primarily by the Drugs and Cosmetics Act, 1940 and the subsequent Rules of 1945, which are constantly evolving to meet global safety and efficacy benchmarks.
Whether you are setting up a state-of-the-art API unit or importing specialized biologics, the complexity of state and central licensing can be a major hurdle. Compliance with Good Manufacturing Practices (GMP) and Good Distribution Practices (GDP) is no longer optional; it's a fundamental requirement for market access.
MedRegX India provides deep expertise in the pharmaceutical lifecycle. We manage your dossiers for Form 25/28, coordinate WHO-GMP audits, and help with export registrations (COPP), ensuring your pharma business stays ahead of the regulatory curve.
Market Access Roadmap
Unit Layout & Approval
Designing the manufacturing facility as per Schedule M and getting the blueprint approved by the State Licensing Authority (SLA).
Manufacturing License (Form 25/28)
Applying for the license to manufacture drugs other than those specified in Schedule C, C(1), and X, ensuring site readiness for inspection.
GMP Certification
Coordinating with the SLA and Central Drugs Standard Control Organisation (CDSCO) for a joint inspection to grant WHO-GMP or National GMP.
COPP & Export Support
Obtaining the Certificate of Pharmaceutical Product (COPP) as per WHO guidelines to facilitate international product registration.
Annual Compliance Tracking
Managing the renewal of licenses, filing annual production returns, and ensuring continuous site updates as per new Pharmacopoeia standards.
Industry Market Access Handbook: Pharmaceuticals & Biologics
The pharmaceutical and biologics industry in India is highly regulated under the provisions of the historical Drugs and Cosmetics Act, 1940 and the parent Drugs Rules, 1945. Governed jointly by the State Licensing Authorities (SLAs) and the Central Drugs Standard Control Organisation (CDSCO), compliance is a strict prerequisites for any manufacturing, distribution, or export operations. All pharmaceutical plants must comply with the Good Manufacturing Practices (GMP) outlined in Schedule M of the Drugs Rules.
Schedule M defines critical statutory standards for facility design, cleanroom air systems (HVAC), water system validation, raw material testing, and product stability. Formulations must undergo rigorous stability testing under climatic Zone IVb conditions to establish shelf life. For companies conducting clinical research or launching New Drugs, compliance with the New Drugs and Clinical Trial Rules, 2019 is mandatory, requiring Form CT-06 approvals prior to initiating clinical phases.
MedRegX provides comprehensive strategic advisory for pharmaceutical stakeholders. We assist with SLA wholesale and manufacturing licenses, WHO-GMP gap assessments, Common Technical Document (CTD) dossier formatting, and pollution board consents, ensuring a smooth path to approval.
Statutory Best Practices
- Adhere strictly to the structural and HVAC guidelines detailed in Schedule M GMP.
- Maintain absolute raw material traceability and validate all water systems (PW/WFI loops).
- Conduct stability testing in strict compliance with Zone IVb climatic specifications.
- Prepare technical dossiers in CTD/eCTD formats for New Drug Applications (NDA).
Critical Standards
| Standard / Rule | Requirement |
|---|---|
| Drugs & Cosmetics Act 1940Primary Law | The overarching legislation that regulates the import, manufacture, distribution, and sale of drugs in India. |
| Schedule M (GMP)Quality Standard | Specifies the requirements for factory premises, plant machinery, and quality control systems for drug manufacturing. |
| Good Distribution Practices (GDP)Supply Chain | Guidelines for the storage and transport of medicinal products to ensure quality is maintained throughout the supply chain. |
Frequently Asked Questions
Have questions? Find direct, humanized answers about the regulatory approvals and timelines.
Pharmaceutical Regulatory Consulting in India
The pharmaceutical sector runs on the Drugs and Cosmetics Act, 1940 and its rules, administered jointly by CDSCO at the centre and State Licensing Authorities. Manufacturing, wholesale, import, and new-drug approval each carry their own licence, and every plant must meet the Good Manufacturing Practices set out in Schedule M.
Licences, GMP, and plant setup
Setting up a pharmaceutical unit means Schedule M compliance from the drawing stage — HVAC air-change rates, purified-water systems, cleanroom classification, and validated processes decided before construction, not retrofitted after. We help with a compliant cGMP plant setup, state manufacturing and wholesale drug licences, and the Site Master Files and process-validation protocols that SLA and CDSCO inspectors expect to see.
For companies running trials or seeking approval for a new drug, the New Drugs and Clinical Trial Rules, 2019 govern the pathway — ethics-committee registration, protocol design, and CT-06 approvals before any phase begins.
Getting audits right the first time
Most pharma delays come down to documentation gaps that surface during a physical inspection. We pre-audit the file, run mock inspections, and close non-conformances before the officer arrives, so your licence is granted on schedule rather than looping through queries. If you are planning a facility or a new formulation, speak to our pharma team before you commit capex.